ETF Holdings Breakdown of KRYS

Stock Name	Krystal Biotech Inc
Ticker	KRYS(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US5011471027
LEI	549300YONUY68210OE41

KRYS institutional holdings

The adjusted close for KRYS on 2025-12-11 was 246.77

The following institutional investment holdings of KRYS have been identified

Date ETF ISIN/Name Num Shares Book value Derived Price per Share Comment
2025-12-11 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 470 USD 115,984 2.9% 246.77

2025-12-11 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 6,220 USD 1,534,941 2.9% 246.78 Incorrect share price reported. Should be 246.77 not 246.78. May be due to incorrect reporting of currency . Could be EUR or USD instead

2025-12-11 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 21,586 1.5% USD 5,326,885 4.4% 246.77

2025-12-11 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 16,605 USD 4,097,699 2.9% 246.78 Incorrect share price reported. Should be 246.77 not 246.78. May be due to incorrect reporting of currency . Could be EUR or USD instead

2025-12-11 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 21,586 1.5% USD 5,326,885 4.4% 246.77

Total = 66,467 USD 16,402,394
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share
2025-12-11	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	470	USD 115,984 2.9%	246.77
2025-12-11	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	6,220	USD 1,534,941 2.9%	246.78 Incorrect share price reported. Should be 246.77 not 246.78. May be due to incorrect reporting of currency . Could be EUR or USD instead
2025-12-11	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	21,586 1.5%	USD 5,326,885 4.4%	246.77
2025-12-11	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	16,605	USD 4,097,699 2.9%	246.78 Incorrect share price reported. Should be 246.77 not 246.78. May be due to incorrect reporting of currency . Could be EUR or USD instead
2025-12-11	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	21,586 1.5%	USD 5,326,885 4.4%	246.77
Total =	66,467	USD 16,402,394

News associated with KRYS

HC Wainwright Reaffirms Buy Rating for Krystal Biotech (NASDAQ:KRYS): Krystal Biotech (NASDAQ:KRYS – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $240.00 target price on the stock. HC Wainwright’s target price suggests a potential upside of 55.46% from the company’s current price. Several other research firms have also […] - 2025-09-17 02:56:43
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $210.38 Average PT from Analysts: Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average […] - 2025-09-11 02:46:50
Chardan Capital Lowers Krystal Biotech (NASDAQ:KRYS) Price Target to $216.00: Krystal Biotech (NASDAQ:KRYS – Free Report) had its price objective trimmed by Chardan Capital from $219.00 to $216.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a buy rating on the stock. Several other research analysts have also issued reports on KRYS. Citigroup reiterated a “neutral” rating and set […] - 2025-08-25 02:58:58
PNC Financial Services Group Inc. Grows Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS): PNC Financial Services Group Inc. grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 27.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 2,141 shares of the company’s stock after acquiring an additional 461 shares during the period. PNC Financial Services Group Inc.’s […] - 2025-08-15 04:48:55
Krystal Biotech (NASDAQ:KRYS) Receives “Neutral” Rating from Citigroup: Krystal Biotech (NASDAQ:KRYS – Get Free Report)‘s stock had its “neutral” rating reiterated by equities researchers at Citigroup in a research note issued to investors on Tuesday, MarketBeat Ratings reports. They presently have a $166.00 price objective on the stock, down from their previous price objective of $176.00. Citigroup’s price target would indicate a potential […] - 2025-08-07 04:30:49
Federated Hermes Inc. Reduces Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS): Federated Hermes Inc. lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 2.0% during the 1st quarter, HoldingsChannel reports. The firm owned 12,781 shares of the company’s stock after selling 267 shares during the period. Federated Hermes Inc.’s holdings in Krystal Biotech were worth $2,304,000 as of its most recent filing with […] - 2025-08-06 06:28:56
Zurcher Kantonalbank Zurich Cantonalbank Has $1.04 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS): Zurcher Kantonalbank Zurich Cantonalbank lowered its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 5.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,742 shares of the company’s stock after selling 312 shares during the period. […] - 2025-08-05 05:06:52
Krystal Biotech (NASDAQ:KRYS) Sees Strong Trading Volume Following Strong Earnings: Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) saw strong trading volume on Monday after the company announced better than expected quarterly earnings. 279,432 shares traded hands during mid-day trading, a decline of 13% from the previous session’s volume of 319,447 shares.The stock last traded at $136.42 and had previously closed at $156.98. The company […] - 2025-08-05 02:20:51
Krystal Biotech Announces Approval Of VYJUVEK In Japan: (RTTNews) - Krystal Biotech (KRYS) announced that Japan's Ministry of Health, Labour and Welfare granted marketing authorization to VYJUVEK for the treatment of wounds in patients with dystrophic epidermolysis bullosa, starting from birth. VYJUVEK is the first genetic medicine ap - 2025-07-25 10:21:36
Teacher Retirement System of Texas Sells 578 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS): Teacher Retirement System of Texas cut its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 9.1% during the 1st quarter, HoldingsChannel.com reports. The fund owned 5,805 shares of the company’s stock after selling 578 shares during the period. Teacher Retirement System of Texas’ holdings in Krystal Biotech were worth $1,047,000 at […] - 2025-07-14 04:46:50
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Allspring Global Investments Holdings LLC: Allspring Global Investments Holdings LLC trimmed its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 82.6% during the first quarter, Holdings Channel reports. The institutional investor owned 5,180 shares of the company’s stock after selling 24,597 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Krystal Biotech were worth […] - 2025-07-09 04:42:14
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by New York State Teachers Retirement System: New York State Teachers Retirement System increased its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 0.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,979 shares of the company’s stock after purchasing an additional 100 shares during the […] - 2025-07-08 05:21:00
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Sold by Illinois Municipal Retirement Fund: Illinois Municipal Retirement Fund cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 9.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 12,762 shares of the company’s stock after selling 1,384 shares during the quarter. Illinois Municipal Retirement […] - 2025-06-30 05:14:49
Krystal Biotech, Inc. (NASDAQ:KRYS) Stock Position Lifted by GAMMA Investing LLC: GAMMA Investing LLC boosted its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 50,249.4% during the first quarter, HoldingsChannel.com reports. The firm owned 121,342 shares of the company’s stock after acquiring an additional 121,101 shares during the period. GAMMA Investing LLC’s holdings in Krystal Biotech were worth $21,878,000 as of its […] - 2025-06-06 06:16:55
Janus Henderson Group PLC Grows Position in Krystal Biotech, Inc. (NASDAQ:KRYS): Janus Henderson Group PLC raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 16.1% during the fourth quarter, HoldingsChannel reports. The firm owned 10,071 shares of the company’s stock after purchasing an additional 1,400 shares during the quarter. Janus Henderson Group PLC’s holdings in Krystal Biotech were worth $1,579,000 as […] - 2025-05-23 05:19:08
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $2.39 Million Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS): MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 1.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,205 shares of the company’s stock after selling 181 shares during the period. […] - 2025-05-22 06:30:46
Deutsche Bank AG Has $3.97 Million Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS): Deutsche Bank AG boosted its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 62.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,361 shares of the company’s stock after acquiring an additional 9,750 shares during the quarter. Deutsche […] - 2025-05-20 05:14:53
Citigroup Has Lowered Expectations for Krystal Biotech (NASDAQ:KRYS) Stock Price: Krystal Biotech (NASDAQ:KRYS – Free Report) had its target price decreased by Citigroup from $215.00 to $155.00 in a research note published on Friday morning,Benzinga reports. Citigroup currently has a neutral rating on the stock. A number of other brokerages have also recently issued reports on KRYS. HC Wainwright reissued a “buy” rating and issued […] - 2025-05-19 02:46:51
Krystal Biotech (NASDAQ:KRYS) Hits New 52-Week Low on Disappointing Earnings: Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) hit a new 52-week low during trading on Tuesday following a weaker than expected earnings announcement. The company traded as low as $137.00 and last traded at $139.47, with a volume of 283299 shares traded. The stock had previously closed at $162.29. The company reported […] - 2025-05-08 02:24:46
Commit To Purchase Krystal Biotech At $150, Earn 16.3% Annualized Using Options: Investors considering a purchase of Krystal Biotech Inc (Symbol: KRYS) stock, but cautious about paying the going market price of $169.11/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in parti - 2025-04-30 12:44:33
102,061 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Purchased by Raymond James Financial Inc.: Raymond James Financial Inc. purchased a new position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 102,061 shares of the company’s stock, valued at approximately $15,989,000. Raymond James Financial Inc. owned approximately 0.35% […] - 2025-04-22 05:45:14
Bank of Montreal Can Increases Stake in Krystal Biotech, Inc. (NASDAQ:KRYS): Bank of Montreal Can grew its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 5.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 3,325 shares of the company’s stock after buying an additional 179 shares during the period. Bank of Montreal Can’s holdings in Krystal Biotech were worth $521,000 […] - 2025-04-22 04:50:52
Krystal Biotech, Inc. (NASDAQ:KRYS) Position Reduced by Invesco Ltd.: Invesco Ltd. reduced its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 24.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 275,195 shares of the company’s stock after selling 90,356 shares during the quarter. Invesco Ltd. owned about […] - 2025-04-17 05:57:00
Federated Hermes Inc. Has $2.04 Million Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS): Federated Hermes Inc. raised its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 1.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 13,048 shares of the company’s stock after purchasing an additional 229 shares during the […] - 2025-04-14 06:20:51
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Acquired by JPMorgan Chase & Co.: JPMorgan Chase & Co. boosted its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 18.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 151,835 shares of the company’s stock after buying an additional 23,934 shares during the period. JPMorgan Chase & Co.’s holdings in Krystal Biotech were worth $23,786,000 as of […] - 2025-04-10 05:07:14
Mitsubishi UFJ Asset Management Co. Ltd. Cuts Position in Krystal Biotech, Inc. (NASDAQ:KRYS): Mitsubishi UFJ Asset Management Co. Ltd. decreased its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 13.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,367 shares of the company’s stock after selling 210 shares during the period. Mitsubishi UFJ […] - 2025-04-04 05:12:57
Sei Investments Co. Sells 13,085 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS): Sei Investments Co. cut its position in Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 38.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 21,164 shares of the company’s stock after selling 13,085 shares during the quarter. Sei Investments Co.’s holdings in Krystal […] - 2025-04-04 04:38:46
4,300 Shares in Krystal Biotech, Inc. (NASDAQ:KRYS) Bought by KLP Kapitalforvaltning AS: KLP Kapitalforvaltning AS acquired a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,300 shares of the company’s stock, valued at approximately $674,000. Other institutional investors also […] - 2025-04-02 05:12:54
Krystal Biotech, Inc. (NASDAQ:KRYS) Shares Bought by Prudential Financial Inc.: Prudential Financial Inc. raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 8.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 41,193 shares of the company’s stock after purchasing an additional 3,254 shares during the quarter. Prudential […] - 2025-03-31 05:22:46
Thrivent Financial for Lutherans Sells 291 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS): Thrivent Financial for Lutherans lessened its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Free Report) by 1.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,563 shares of the company’s stock after selling 291 shares during the quarter. Thrivent Financial […] - 2025-03-27 05:52:53

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.